PARIS/BOSTON (Reuters) - Biotech company Genzyme Inc rejected an $18.5 billion buyout offer from French drugmaker Sanofi-Aventis SA on Monday, setting the stage for a protracted and potentially ...

BOSTON, July 31 (Reuters) - The U.S. Food and Drug Administration has notified Genzyme Corp that it will re-inspect a key manufacturing plant because the biotechnology company did not take sufficient ...

CAMBRIDGE, Mass. – Genzyme Corp. (Nasdaq: GENZ) today announced that it has established a program to participate in efforts to discover and advance novel treatments for neglected diseases affecting ...

When the French pharmaceutical giant Sanofi starts moving 2,500 employees from 10 sites in Massachusetts into a pair of new buildings in East Cambridge next month, visitors may notice something ...

In an ironic twist, Genzyme (www.genzyme.com) first battled through its acquisition of Bioenvision and is now basking in the glory of speculations over big pharma’s interest in gobbling up biologic ...

What would you do if you operated a French pharmaceutical company that lost patent protection on its key drugs, laid off 2,500 workers by conference call, seen its most hyped cancer drug fail to meet ...

Sanofi-Aventis agreed to buy Genzyme Corp., ending a nine-month pursuit of the U.S. biotechnology company with a sweetened offer of at least $20.1 billion that gives France's biggest drugmaker ...

Bayer stands to earn up to $1.9 billion dependent on approval and sales achievements. Genzyme is taking over worldwide rights from Bayer HealthCare covering Campath® (alemtuzumab), which is approved ...

(AP) — Biotechnology company Genzyme Corp. said Friday it hired Ron Branning as senior vice president of global product quality. Branning will oversee quality control for Genzyme products made at 17 ...

How do you whittle 35 years of headlining business news down to a couple thousand words and a few pages? You don't. But here, we take our best shot to highlight the companies, individuals, and moments ...

On November 25, 2025, Sarepta Therapeutics filed two petitions for inter partes review (“IPR”) challenging Genzyme’s patents relating to the characterization of recombinant adeno-associated virus ...

A 25,000-square-foot office building in Framingham that formerly housed the drugmaker Genzyme has sold for $3.2 million. The buyer is a limited liability corporation, called 11 Pleasant Street ...